Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 948

Similar articles for PubMed (Select 17928318)

1.

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC.

Brain. 2007 Nov;130(Pt 11):2837-44. Epub 2007 Oct 10.

2.

Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.

Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, Jones G, O'Keefe G, Masters CL, Ames D, Ellis KA, Maruff P, Currie J, Villemagne VL, Rowe CC, Salvado O, Ourselin S.

Neuroimage. 2008 Nov 15;43(3):430-9. doi: 10.1016/j.neuroimage.2008.07.053. Epub 2008 Aug 12.

PMID:
18789389
3.

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC.

Neuropsychologia. 2008;46(6):1688-97. doi: 10.1016/j.neuropsychologia.2008.02.008. Epub 2008 Feb 14.

PMID:
18343463
4.

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.

Forsberg A, Almkvist O, Engler H, Wall A, Långström B, Nordberg A.

Curr Alzheimer Res. 2010 Feb;7(1):56-66.

PMID:
20205671
5.

Imaging beta-amyloid burden in aging and dementia.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL.

Neurology. 2007 May 15;68(20):1718-25.

PMID:
17502554
6.

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.

Pike KE, Ellis KA, Villemagne VL, Good N, Chételat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC.

Neuropsychologia. 2011 Jul;49(9):2384-90. doi: 10.1016/j.neuropsychologia.2011.04.012. Epub 2011 Apr 16.

PMID:
21529702
7.

Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment.

Tolboom N, van der Flier WM, Yaqub M, Koene T, Boellaard R, Windhorst AD, Scheltens P, Lammertsma AA, van Berckel BN.

Neurology. 2009 Dec 15;73(24):2079-85. doi: 10.1212/WNL.0b013e3181c679cc.

PMID:
20018636
8.

PET imaging of amyloid deposition in patients with mild cognitive impairment.

Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A.

Neurobiol Aging. 2008 Oct;29(10):1456-65. Epub 2007 May 11.

PMID:
17499392
9.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
10.

The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Villemagne VL, Fodero-Tavoletti MT, Pike KE, Cappai R, Masters CL, Rowe CC.

Mol Neurobiol. 2008 Aug;38(1):1-15. doi: 10.1007/s12035-008-8019-y. Epub 2008 Aug 9. Review.

PMID:
18690556
11.

Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.

Tolboom N, Yaqub M, van der Flier WM, Boellaard R, Luurtsema G, Windhorst AD, Barkhof F, Scheltens P, Lammertsma AA, van Berckel BN.

J Nucl Med. 2009 Feb;50(2):191-7. doi: 10.2967/jnumed.108.056499. Epub 2009 Jan 21.

12.

Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease.

Drzezga A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschläger A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A.

Neurology. 2009 Apr 28;72(17):1487-94. doi: 10.1212/WNL.0b013e3181a2e8d0. Epub 2009 Apr 1.

PMID:
19339712
13.

In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S.

Am J Geriatr Psychiatry. 2004 Nov-Dec;12(6):584-95.

PMID:
15545326
14.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

15.

Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment.

Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S.

Curr Alzheimer Res. 2009 Jun;6(3):312-9. Review.

PMID:
19519314
16.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

17.

PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment.

Koivunen J, Pirttilä T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, Hänninen T, Hallikainen M, Någren K, Rinne JO, Soininen H.

Dement Geriatr Cogn Disord. 2008;26(4):378-83. doi: 10.1159/000163927. Epub 2008 Oct 16.

PMID:
18931497
18.

Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.

Hatashita S, Yamasaki H.

J Alzheimers Dis. 2010;21(3):995-1003. doi: 10.3233/JAD-2010-100222.

PMID:
20693641
19.

MR-less high dimensional spatial normalization of 11C PiB PET images on a population of elderly, mild cognitive impaired and Alzheimer disease patients.

Fripp J, Bourgeat P, Raniga P, Acosta O, Villemagne V, Jones G, O'keefe G, Rowe C, Ourselin S, Salvado O.

Med Image Comput Comput Assist Interv. 2008;11(Pt 1):442-9.

PMID:
18979777
20.

Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease.

Ng S, Villemagne VL, Berlangieri S, Lee ST, Cherk M, Gong SJ, Ackermann U, Saunder T, Tochon-Danguy H, Jones G, Smith C, O'Keefe G, Masters CL, Rowe CC.

J Nucl Med. 2007 Apr;48(4):547-52.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk